Search | Clinical Trials Finder

Conditions: Osteoarthritis, Arthritis
Interventions: NSAID, tanezumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 250
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more

Conditions: Heart Failure, Heart Failure, Congestive, Heart Failure, Systolic
Interventions: VITARIA System; Device
Lead sponsor: LivaNova; Industry
Eligibility: 18 Years and older
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 22
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 19 more

Conditions: Young Adults, Hypertension, Post-Exercise Hypotension, Circadian Rhythm
Interventions: Exercise; Behavioral
Lead sponsor: Freda Patterson; Other
Eligibility: 18 Years to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Obesity
Interventions: Blocked, Intact; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Interventions: Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 40 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: phenylephrine and clonidine, punch biopsy; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: ME/CFS, Long COVID, PASC
Interventions: Pyridostigmine, Low-Dose Naltrexone, Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Takotsubo Syndrome
Interventions: Tako Breath; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Spinal Cord Injury, Stroke, Amputees
Interventions: Therapy Sessions; Device
Lead sponsor: Brooks Rehabilitation; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Jacksonville, Florida • Tampa, Florida

Conditions: Traumatic Brain Injury, Dysautonomia
Interventions: Esmolol, Propranolol; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Adenocarcinoma
Interventions: Retifanlimab, Chemotherapy, 9-ING-41; Drug
Lead sponsor: Anwaar Saeed; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Postexercise Hypotension
Interventions: Aerobic Exercise, alpha-FMH, Resistance and Aerobic Exercise, Antihistamine; Behavioral · Drug
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Breast Cancer
Interventions: Paclitaxel, BKM120 matching placebo, BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 21
States / cities: Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more

Conditions: Orthostatic Hypotension
Interventions: water high dose, water tiny dose; Other
Lead sponsor: Satish R. Raj; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Human Immunodeficiency Virus, Smoking Cessation, Smoking, Cigarette, Smoking, Anxiety, Depression, Nicotine Dependence
Interventions: QUIT, Time-Matched Control (TM); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Obstructive Sleep Apnea
Interventions: continuous positive airway pressure (CPAP); Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alcohol Use Disorder
Interventions: Cervical transcutaneous vagus nerve stimulation (active comparator), Cervical transcutaneous vagus nerve stimulation (sham comparator); Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Diego, California

Conditions: Impact of Singing, Cardiovascular Health, Cardiovascular Risk Factors, Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Multiple System Atrophy
Interventions: TEV-56286, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more

Conditions: Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
Interventions: Droxidopa, Placebo; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 44
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more

Conditions: Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy
Interventions: [18F]MNI-1216; Drug
Lead sponsor: Invicro; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cluster Headache
Interventions: There are no interventions in the observational study. The symptom of allodynia was measured.; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: POTS - Postural Orthostatic Tachycardia Syndrome
Interventions: Questionnaires to be competed, Provide list of medication and lifetime events, Use phone App to record new life events, Will wear an activity monitor, Periodic 24-hour urine sodium check, A fMRI scan, A bedside tilt test will be performed, IV placed to collect blood samples, Stool Sample; Behavioral · Device · Other + 1 more
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance
Interventions: Droxidopa, Atenolol, Placebos; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

ANTHEM-HFrEF Pivotal Study

Examining the Circadian Timing Effects of the Hypotensive Response to Exercise

The Autonomic Nervous System and the Metabolic Syndrome

Autonomic and Renal Contributions to Hypertension With ADT

Mechanism and Treatment of Sympathetically Maintained Pain

LIFT: Life Improvement Trial

Autonomic Modulation in Takotsubo Syndrome

Effect of Neuro20 Functional Electrical Stimulation Suit on Autonomic Function, Muscle Performance, and Gait

Controlling Hyperadrenergic Activity in Neurologic Injury

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

Histamine as a Molecular Transducer of Adaptation to Exercise

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Water and the Gastropressor Response - Tachyphylaxis

Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV

Autonomic Function in Obstructive Sleep Apnea

Non-invasive Vagal Nerve Stimulation as Novel Treatment to Improve Functional Outcomes in Veterans With Alcohol Use Disorder

The Singing Heart Study

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain

A Research Study to Examine Cutaneous Allodynia and Cluster Headache

Does a Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Nat hx With Its Numerous Co-morbidities?

Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist